Scientific Sessions 2024  /  GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics  /  Panel Discussion
Logo

American Heart Association

  2
  0

Final ID:

Panel Discussion

  • Tuttle, Katherine  ( PROVIDENCE MEDICAL RESEARCH CENTER , Spokane , Washington , United States )
    • Author Disclosures:
    Katherine Tuttle: DO have relevant financial relationships ; Consultant:Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Past (completed) ; Research Funding (PI or named investigator):Travere:Active (exists now) ; Consultant:Pfizer:Past (completed) ; Consultant:Astra Zeneca:Past (completed) ; Consultant:ProKidney:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Eli Lilly and Company:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics

Sunday, 11/17/2024 , 09:45AM - 11:00AM

Main Event

More abstracts on this topic:
Access and Equity: real world implications of the coverage and cost of incretin mimetics

Powell-wiley Tiffany, Essien Utibe

Patient Interview

Ndumele Chiadi, Taub Pam

More abstracts from these authors:
Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial

Tuttle Katherine, Mann Johannes, Perkovic Vlado, Pratley Richard, Ridker Paul, Rossing Peter, Schmieder Roland, Shamkhalova Minara S., Sreenivasamurthy L, Mahaffey Kenneth, Bakris George, Bang Casper, Bax Willem, Belmar Nicolas, Brown Paul, Cherney David, Chernin Gil, Lim Soo Kun

Going with the FLOW: Understanding the renal effects of GLP-1RA therapy

Tuttle Katherine, Rangaswami Janani

You have to be authorized to contact abstract author. Please, Login
Not Available